CL2016002562A1 - Régimen de dosificación de liberación inmediata de moduladores s1p. - Google Patents

Régimen de dosificación de liberación inmediata de moduladores s1p.

Info

Publication number
CL2016002562A1
CL2016002562A1 CL2016002562A CL2016002562A CL2016002562A1 CL 2016002562 A1 CL2016002562 A1 CL 2016002562A1 CL 2016002562 A CL2016002562 A CL 2016002562A CL 2016002562 A CL2016002562 A CL 2016002562A CL 2016002562 A1 CL2016002562 A1 CL 2016002562A1
Authority
CL
Chile
Prior art keywords
modulators
immediate release
dosing regime
regime
dosing
Prior art date
Application number
CL2016002562A
Other languages
English (en)
Spanish (es)
Inventor
Eric Legangneux
Philippe Michel Rene Bouillot
Emeric Reynaud
Erik Walstroem
Frank Dahlke
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52988364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016002562(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2016002562A1 publication Critical patent/CL2016002562A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2016002562A 2014-04-10 2016-10-07 Régimen de dosificación de liberación inmediata de moduladores s1p. CL2016002562A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461977816P 2014-04-10 2014-04-10

Publications (1)

Publication Number Publication Date
CL2016002562A1 true CL2016002562A1 (es) 2017-07-28

Family

ID=52988364

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002562A CL2016002562A1 (es) 2014-04-10 2016-10-07 Régimen de dosificación de liberación inmediata de moduladores s1p.

Country Status (16)

Country Link
US (4) US20170027907A1 (https=)
EP (3) EP4074312B1 (https=)
JP (1) JP6674903B2 (https=)
KR (2) KR20160141841A (https=)
CN (2) CN106456552A (https=)
AU (2) AU2015246036A1 (https=)
CA (1) CA2943598C (https=)
CL (1) CL2016002562A1 (https=)
IL (2) IL305337A (https=)
MX (1) MX2016013245A (https=)
PH (1) PH12016501965A1 (https=)
RU (2) RU2715734C2 (https=)
SG (1) SG11201607894RA (https=)
TW (1) TW201622721A (https=)
WO (1) WO2015155709A1 (https=)
ZA (1) ZA201606519B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (https=) 2014-01-24 2018-02-24
MX2016013245A (es) * 2014-04-10 2017-01-16 Novartis Ag Regimen de dosificacion de liberacion inmediata de moduladores s1p.
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
MX2020007268A (es) * 2017-09-29 2020-08-17 Novartis Ag Regimen de dosificacion de siponimod.
AU2018343239A1 (en) * 2017-09-29 2020-03-12 Novartis Ag Dosing regimen of siponimod
KR20250002710A (ko) * 2018-03-01 2025-01-07 아스트라제네카 에이비이 (2s)-n-｛(1s)-1-시아노-2-[4-(3-메틸-2-옥소-2,3-디하이드로-1,3-벤족사졸-5-일)페닐]에틸｝-1,4-옥사제판-2-카복스아미드를포함하는 약학 조성물
AU2019306532A1 (en) 2018-07-17 2021-03-04 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating Lupus Nephritis
CN109908095A (zh) * 2019-04-08 2019-06-21 肇庆学院 一种西尼莫德片剂及制备方法
AU2020372647B2 (en) 2019-10-31 2026-02-05 Idorsia Pharmaceuticals Ltd Combination of a CXCR7 antagonist with an S1P1 receptor modulator
WO2021158838A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Dosage regimen of an s1p receptor modulator
EP4646265A1 (en) 2023-01-06 2025-11-12 Insmed Incorporated Novel, reversible dpp1 inhibitors and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2676953T (pt) * 2008-12-18 2017-06-29 Novartis Ag Sal hemifumarato de ácido 1-[4-[1-(4-ciclo-hexil-3-trifluorometil-benziloxi-imino)-etil]-2-etil-benzil]-azetidino-3-carboxílico para utilização no tratamento de doenças mediadas por linfócitos
CN105213372A (zh) 2008-12-22 2016-01-06 诺华股份有限公司 S1p受体激动剂的给药方案
RS66784B9 (sr) * 2008-12-22 2025-08-29 Novartis Ag Režim doziranјa agonista s1p receptora
EP2482810A2 (en) * 2009-09-29 2012-08-08 Novartis AG Dosage regimen of an s1p receptor modulator
BR112013017302B1 (pt) * 2011-01-07 2021-12-07 Novartis Ag Composição farmacêutica em fase sólida
WO2012095853A1 (en) * 2011-01-10 2012-07-19 Novartis Pharma Ag Modified release formulations comprising sip receptor modulators
PH12014500854A1 (en) * 2011-10-21 2021-08-09 Novartis Ag Dosage regimen for an s1p receptor modulator or agonist
MX2016013245A (es) * 2014-04-10 2017-01-16 Novartis Ag Regimen de dosificacion de liberacion inmediata de moduladores s1p.

Also Published As

Publication number Publication date
AU2015246036A1 (en) 2016-10-13
EP4074312B1 (en) 2026-02-25
PH12016501965A1 (en) 2017-01-09
IL305337A (en) 2023-10-01
AU2020203107A1 (en) 2020-05-28
EP3129020A1 (en) 2017-02-15
CN106456552A (zh) 2017-02-22
US20170027907A1 (en) 2017-02-02
AU2020203107B2 (en) 2021-10-21
US20190054065A1 (en) 2019-02-21
EP3831378A1 (en) 2021-06-09
JP6674903B2 (ja) 2020-04-01
RU2016143979A3 (https=) 2018-11-12
KR20220156981A (ko) 2022-11-28
RU2715734C2 (ru) 2020-03-03
SG11201607894RA (en) 2016-10-28
RU2020107732A (ru) 2020-03-30
CA2943598A1 (en) 2015-10-15
WO2015155709A1 (en) 2015-10-15
US20220016076A1 (en) 2022-01-20
JP2017510607A (ja) 2017-04-13
IL247986A0 (en) 2016-11-30
EP4074312C0 (en) 2026-02-25
US20250041266A1 (en) 2025-02-06
TW201622721A (zh) 2016-07-01
KR20160141841A (ko) 2016-12-09
EP4074312A1 (en) 2022-10-19
ZA201606519B (en) 2017-11-29
CA2943598C (en) 2023-03-07
MX2016013245A (es) 2017-01-16
RU2016143979A (ru) 2018-05-14
CN116650467A (zh) 2023-08-29

Similar Documents

Publication Publication Date Title
PL3177329T3 (pl) Układ do natychmiastowego uwalniania substancji aktywnych
CL2016002562A1 (es) Régimen de dosificación de liberación inmediata de moduladores s1p.
MA43382A (fr) Modulateurs des récepteurs des chimiokines
DK3331876T3 (da) Modulators of ror-gamma
HUE061287T2 (hu) Újratöltõ csomag e-cigarettához
MA53943A (fr) Modulateurs de ror-gamma
EP3888782C0 (en) COATED MICROCAPSULES
DK3236943T3 (da) Sammensætninger til ileo-jejunal lægemiddeladministration
DK3131902T3 (da) Forbindelser som ROR-gamma-modulatorer
EP3868427C0 (en) SAFETY SYRINGE SYSTEM
DK3229810T3 (da) Phospholipid-ether-analoger som kræftrammende lægemiddelvehikler
HUE043290T2 (hu) Adagoló kapszula
DK3125898T3 (da) Farmakofor til trail-induktion
ES1137034Y (es) Cápsula para sólidos
DK3145488T3 (da) Flydende farmaceutiske forbindelse
BR112016020077A2 (pt) composições de lactase líquida
DK3230929T3 (da) Forbedringer til tælleranordninger
MA41266A (fr) Cataplasme
DK3145916T3 (da) Imidazolderivater som formylpeptidreceptormodulatorer
DK2946774T3 (da) Coatede kapsler med modificeret frigivelse
FR3030466B3 (fr) Valve doseuse multilame
DE112015005590A5 (de) Dosierpumpe
EP3181125C0 (en) CAPSULE FORMULATION
DK3089740T3 (da) Farmaceutisk sammensætning
FR3029792B1 (fr) Liberation maitrisee de substances actives.